Episodes (Page 8)
✨
US FDA CBER leadership changes and potential future directions were analyzed.
Vinay Prasad
✨
Onchilles Pharma discusses their neutrophil-derived pan-cancer therapy.
Court Turner
Lev Becker
✨
Small companies eye European expansion under Most Favored Nation (MFN) status.
✨
Smaller firms consider European expansion under MFN terms.
✨
Former FDA executives discuss the current state of facility inspections.
Douglas Stearn
Michael Rogers
✨
Europe's probiotic market is dynamic but faces complex regulations.
David Pineda Ereno
✨
Zealand CEO calls for an end to the 'weight loss Olympics'.
✨
Zealand CEO advocates for ending the 'weight loss Olympics'.
✨
The future direction and priorities of the generic industry were discussed.
✨
Affibody CEO discusses antibody mimetics for radioligand therapy.
David Bejker
✨
Global pharma faces headwinds in 2026 due to patent expiries.
✨
Hudson's legacy at Sanofi and Trump's pharma investment realities were discussed.
✨
Hudson's impact at Sanofi and realities of Trump's pharma investment push.
✨
FDA user fee proposals align with Trump's priorities, raising concerns.
✨
Scrip highlights R&D innovation, Bayer's stroke research, and AstraZeneca's oncology strategy.
✨
Scrip covers R&D innovation, Bayer's stroke trial results, and AstraZeneca's oncology focus.
✨
Hansa Biopharma CEO discusses their lead asset for kidney transplants.
Renee Aguiar-Lucander
✨
Consumer willingness to pay for sustainable products varies by market.
Steve Ramus
✨
FDA's refusal to file Moderna's flu vaccine sparks debate on RTF actions.
✨
Airway Therapeutics CEO discusses zelpultide alfa for preventing BPD in preterm infants.